欧洲泌尿生殖放射学会(ESUR)指南:宫颈癌、子宫内膜癌和卵巢癌患者保留生育功能治疗前的MR成像
欧洲泌尿生殖放射学会女性盆腔工作组采用RAND-UCLA适宜性方法,由10名放射科医生和2名妇科肿瘤医生组成多学科小组,系统复习截至2025年2月28日的文献,并通过涵盖MR成像准备、设备规格、序列方案和报告标准的104个问题调查制定指南。共识推荐了MRI技术要求和疾病特异性结构化报告模板,旨在标准化MRI采集与报告以支持宫颈癌、子宫内膜癌和卵巢癌患者保留生育功能治疗的最佳选择。
要点
- MRI是评估宫颈癌和子宫内膜癌保留生育功能治疗资格标准的关键手段。
- 关键参数包括精确肿瘤测量、浸润深度和局部肿瘤范围,需优化解剖与功能序列组合。
- 采用疾病特异性结构化报告模板,标准化宫颈癌、子宫内膜癌和卵巢癌的MRI报告。
核心结论
- 这些基于证据的指南为MRI采集和报告提供了标准化框架,以支持妇科癌症患者保留生育功能治疗的最佳患者选择。
- 通过统一成像方案和结构化报告,旨在提高诊断准确性和临床决策。
研究设计与样本
- 欧洲泌尿生殖放射学会(ESUR)女性盆腔工作组采用RAND-UCLA适宜性方法制定指南。
- 多学科小组由10名放射科医生和2名妇科肿瘤医生组成,系统复习截至2025年2月28日的临床和影像文献。
- 通过涵盖MR成像准备、设备规格、序列方案和报告标准的5个部分共104个问题的结构化调查评估MRI方案。
诊断标准与关键数值
- 共识推荐了MRI技术要求,包括序列选择、成像平面和对比剂时机。
- 制定了宫颈癌、子宫内膜癌和卵巢癌的疾病特异性结构化报告模板及标准化标准。
- 达成≥80%共识的建议定为「RECOMMENDED」,低于该阈值的标记为「SUGGESTED」或「NOT RECOMMENDED」。
临床应用与阅片要点
- MRI可用于妇科癌症患者保留生育功能治疗前的术前评估,关键参数包括精确肿瘤测量、浸润深度和局部肿瘤范围。
- 宫颈癌和子宫内膜癌的保留生育功能治疗需遵循基于肿瘤分期、大小和组织学亚型的严格选择标准。
- 卵巢附件肿块应采用标准化报告标准进行表征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To establish standardised MRI protocols and structured reporting guidelines for optimal patient selection in fertility-sparing treatments for gynaecological cancers.
METHODS: The European Society of Urogenital Radiology (ESUR) Female Pelvis Working Group utilised the RAND-UCLA Appropriateness Method to develop these guidelines. A multidisciplinary panel composed of ten radiologists and two gynaecological oncologists conducted a comprehensive review of clinical and imaging literature (until 28th February 2025) and evaluated MRI protocols through a structured survey consisting of 104 questions across five sections covering MR imaging preparation, equipment specifications, protocols, and reporting standards. Recommendations achieving ≥ 80% consensus were designated as "RECOMMENDED", with those below this threshold marked as "SUGGESTED" or "NOT RECOMMENDED".
RESULTS: Consensus was reached on MRI technical requirements, including sequence selection, imaging planes, and contrast timing. Disease-specific structured reporting templates were developed with standardised criteria for cervical, endometrial and ovarian cancers.
CONCLUSIONS: These evidence-based guidelines provide a standardised framework for MRI acquisition and reporting to support optimal patient selection for fertility-sparing treatments. By harmonising imaging protocols and structured reporting, we aim to enhance diagnostic accuracy and clinical decision-making. These guidelines represent a key step toward developing comprehensive recommendations for fertility preservation, with future validation and adaptation ensuring their applicability across diverse clinical settings.
KEY POINTS: Question Fertility-sparing treatments in gynaecological cancers require adherence to strict selection criteria based on tumour stage, size, and histological subtype. Findings MRI is essential for accurately assessing eligibility criteria in cervical and endometrial cancers, and characterising adnexal masses using standardised reporting criteria. Clinical relevance MRI is valuable for the preoperative evaluation of patients considered for fertility-sparing treatments in gynaecologic cancers. Key parameters include precise tumour measurements, depth of invasion, and local tumour extent through optimised protocols combining anatomical and functional sequences.
引用
- Gui B, Russo L, Bharwani N, et al. European Society of Urogenital Radiology (ESUR) guidelines on MR imaging prior to fertility-sparing treatments in patients with cervical, endometrial, and ovarian cancers. Eur Radiol. 2025. PMID: 40358675. doi:10.1007/s00330-025-11625-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。